{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:03:27Z","timestamp":1790334207081,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.dmd.2026.100370","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:11:30Z","timestamp":1784329890000},"page":"100370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing 14C-radiochemical doses for absorption, distribution, metabolism, and excretion studies: A predictive approach"],"prefix":"10.1016","volume":"54","author":[{"given":"Alfin D.N.","family":"Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia E.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenalo T.A.","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine L.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim F.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dmd.2026.100370_bib1","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/cts.13403","article-title":"Human radiolabeled mass balance studies supporting the FDA approval of new drugs","volume":"15","author":"Ramamoorthy","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2026.100370_bib2","article-title":"Clinical pharmacology considerations for human radiolabeled mass balance studies guidance for industry","year":"2024","journal-title":"Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.dmd.2026.100370_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.70157","article-title":"Guided sample pooling in human mass balance studies: a recommended strategic decision framework","volume":"119","author":"Cuyckens","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100370_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/cts.12549","article-title":"Novel application of the two-period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin","volume":"11","author":"Raje","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100370_bib5","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1128\/AAC.03300-14","article-title":"Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB\/ParE inhibitor in rats","volume":"58","author":"Malfatti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100370_bib6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/clpt.1981.56","article-title":"Determination of mean valproic acid serum level by assay of a single pooled sample","volume":"29","author":"Hamilton","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100370_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2026.100389","article-title":"The absorption, distribution, metabolism, excretion and pharmacokinetic properties of the pan-RAF inhibitor naporafenib in healthy subjects: an absolute bioavailability and mass balance study","author":"Lam","year":"2026","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100370_bib46","article-title":"A study to evaluate relative bioavailability of three naporafenib (LXH254) formulations in healthy subjects. Poster presented at: American Society for Clinical Pharmacology and Therapeutics 2025 Annual Meeting;","author":"Nakhla","year":"2025","journal-title":"National Harbor, MD. Poster PI-026"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers","volume":"9","author":"Fox","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.dmd.2026.100370_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/00498254.2016.1179821","article-title":"Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects","volume":"47","author":"Morcos","year":"2017","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.dmd.2026.100370_bib11","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/jcph.1286","article-title":"Effect of hepatic impairment on the pharmacokinetics of alectinib","volume":"58","author":"Morcos","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100370_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/cpdd.630","article-title":"An open-label, single-dose, human mass balance study of amenamevir in healthy male adults","volume":"8","author":"Kato","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"10.1016\/j.dmd.2026.100370_bib13","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1007\/s12325-017-0643-3","article-title":"The influence of hepatic and renal impairment on the pharmacokinetics of a treatment for herpes zoster, amenamevir (ASP2151): phase 1, open-label, single-dose, parallel-group studies","volume":"34","author":"Kusawake","year":"2017","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab and Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100370_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban pharmacokinetics and pharmacodynamics in subjects with mild or moderate hepatic impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R D"},{"issue":"12","key":"10.1016\/j.dmd.2026.100370_bib16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3109\/00498254.2011.604745","article-title":"Disposition, metabolism and mass balance of [14C]apremilast following oral administration","volume":"41","author":"Hoffmann","year":"2011","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmd.2026.100370_bib17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/cts.13013","article-title":"Pharmacokinetics and tolerability of apremilast in healthy Korean adult men","volume":"14","author":"Huh","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100370_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70382","article-title":"Mass balance and metabolism of 14C-atogepant in healthy male participants: findings of a phase 1 clinical trial","volume":"18","author":"Boinpally","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib19","article-title":"Atogepant: mechanism of action, clinical and translational science","volume":"17","author":"Boinpally","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.dmd.2026.100370_bib20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.122.001240","article-title":"Mass balance and absorption, distribution, metabolism, and excretion properties of balcinrenone following oral administration in combination with intravenous microtracer in healthy subjects","volume":"51","author":"Lindmark","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100370_bib21","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/bcp.70017","article-title":"The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone","volume":"91","author":"Bhattacharya","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"9-11","key":"10.1016\/j.dmd.2026.100370_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/00498254.2022.2159569","article-title":"Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection","volume":"52","author":"Subramanian","year":"2022","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1128\/aac.00781-25","article-title":"The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a phase 1, open-label, drug\u2013drug interaction study","volume":"70","author":"Arora","year":"2026","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100370_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/00498254.2022.2062487","article-title":"Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans","volume":"52","author":"Ryder","year":"2022","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmd.2026.100370_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpdd.782","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a liver-targeting acetyl-CoA carboxylase inhibitor (PF-05221304): a three-part randomized phase 1 study","volume":"9","author":"Bergman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/00498254.2014.941964","article-title":"Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects","volume":"45","author":"Johnson","year":"2015","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmd.2026.100370_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.120.000309","article-title":"Metabolism and mass balance of the novel nonsteroidal androgen receptor inhibitor darolutamide in humans","volume":"49","author":"Taavitsainen","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100370_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-021-01078-y","article-title":"Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment","volume":"61","author":"Zurth","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13318-024-00930-3","article-title":"Mass balance recovery, absorption, metabolism, and excretion of elinzanetant in healthy human volunteers and in vitro biotransformation","volume":"50","author":"Schulz","year":"2025","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"10.1016\/j.dmd.2026.100370_bib32","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/00498254.2016.1261307","article-title":"Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration","volume":"47","author":"Lam","year":"2017","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100370_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00280-018-3748-8","article-title":"Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study","volume":"83","author":"Shaik","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100370_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/00498254.2014.999141","article-title":"Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers","volume":"45","author":"Chen","year":"2015","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100370_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor; (Table 2). Clin","volume":"53","author":"Scheen","year":"2014","journal-title":"Pharmacokinet"},{"issue":"15","key":"10.1016\/j.dmd.2026.100370_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2217\/fon-2020-0877","article-title":"Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors","volume":"17","author":"Liu","year":"2021","journal-title":"Fut Oncol"},{"key":"10.1016\/j.dmd.2026.100370_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-014-0181-7","article-title":"Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas","volume":"33","author":"Dubbelman","year":"2015","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.dmd.2026.100370_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s13318-021-00747-4","article-title":"A phase I study to evaluate the pharmacokinetics and safety of lorlatinib in adults with mild, moderate, and severe renal impairment","volume":"47","author":"Lin","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmd.2026.100370_bib39","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.1621","article-title":"Metabolism, excretion, and pharmacokinetics of lorlatinib (PF-06463922) and evaluation of the impact of radiolabel position and other factors on comparability of data across 2 ADME studies","volume":"60","author":"Stypinski","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100370_bib40","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/bcp.70020","article-title":"Oral paltusotine, a nonpeptide selective somatostatin receptor 2agonist: mass balance, absolute bioavailability and metabolism in healthy participants","volume":"91","author":"Luo","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100370_bib41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/j.dmd.2026.100370_bib42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/00498254.2022.2132187","article-title":"Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900) following a single oral dose in healthy male participants","volume":"52","author":"Mutch","year":"2022","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmd.2026.100370_bib43","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.jaci.2021.10.038","article-title":"Maetzel A, Smith MD, Duckworth EJ, et al. KVD900, an oral on-demand treatment for hereditary angioedema: phase 1 study results","volume":"149","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100370_bib44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans","volume":"42","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100370_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cpdd.741","article-title":"Phase 1 dose-escalation study to evaluate the pharmacokinetics, safety, and tolerability of tofacitinib in Japanese healthy volunteers","volume":"9","author":"Miyoshi","year":"2019","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:15:41Z","timestamp":1790331341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0090955626006392"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100370","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing 14C-radiochemical doses for absorption, distribution, metabolism, and excretion studies: A predictive approach","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100370"}}